Federal court strikes down Trump rule that drugmakers disclose price
In a major legal setback for President Donald Trump on a high-profile consumer issue, a federal appeals court has ruled that his administration lacks the legal authority to force drug companies to disclose prices in their TV ads.
Trump administration wants to import cheaper prescription drugs from abroad
Health officials unveiled a proposed regulation that would allow states to import many brand name drugs from Canada, with federal oversight.
Watch 6:26
News Wrap: House opens debate on bill to lower prescription drug costs
In our news wrap Wednesday, the House opened debate on a Democratic bill to lower prescription drug costs through government negotiations. House Speaker Nancy Pelosi appealed for bipartisan support, but Sen. Mitch McConnell said he won’t bring the bill up…
WATCH: Patients affected by rising drug prices testified before House committee
The hearing on Capitol Hill comes at a time when the Trump administration has made a push to reduce drug prices and the cost of healthcare overall.
This week, the Trump administration reversed its position on reforming the drug rebate system. Analysts and advocates say there may be better approaches to lower out-of-pocket costs.
The U.S. Centers for Medicare & Medicaid Services is requiring drug makers to include “list prices” in television ads for all medicines covered by Medicare or Medicaid that cost $35 or more.
Together, the pharmaceutical companies that testified before Congress this week earn billions of dollars treating the world’s maladies and operating under the premise that today’s profits will fund research and development for tomorrow’s cures. But at what price?…
Health care costs are a major concern for Americans, who spend more on prescription drugs than residents of any other country. On Tuesday, executives from seven of the biggest pharmaceutical companies appeared before a Senate committee to explain their rising…
Some drugmakers have blocked competition for their medications by preventing would-be competitors from obtaining samples of the drugs. Drug executives who testified before Congress Tuesday said they do not use this tactic.
Additional Support Provided By:
